2026-10-10T05:03:39Z https://api.figshare.com/v2/oai

oai:figshare.com:article/33979756 2026-09-24T04:43:16Z category_658 portal_316 item_type_3 month_year_09_2026

Data Sheet 2_A malignancy risk prediction model for Bethesda category III thyroid nodules based on serological indicators, C-TIRADS, and BRAF V600E testing.pdf Wei Yang (109917) Chun Jin Xiong (25101673) Shuang Shuang Dong (25101676) Bin Sheng (540352) Cell Metabolism Bethesda category III BRAF V600E C-TIRADS multimodal model TgAb thyroid nodules TPOAb Objective<p>To investigate the diagnostic value of a multimodal prediction model integrating thyroglobulin antibody (TgAb), thyroid peroxidase antibody (TPOAb), the Chinese Thyroid Imaging Reporting and Data System (C-TIRADS), and BRAF V600E mutation status, for evaluating the malignancy risk in Bethesda Category III thyroid nodules.</p>Methods<p>We retrospectively enrolled 93 patients whose thyroid nodules were diagnosed as Bethesda Category III via fine-needle aspiration and subsequently underwent surgical treatment at Northern Jiangsu People’s Hospital between July 2020 and June 2025. Preoperative TgAb levels, TPOAb levels, C-TIRADS classification, and BRAF V600E mutation status data were collected. A malignancy risk prediction model was constructed using Firth’s penalized likelihood logistic regression. The diagnostic performance of individual indicators and the combined model was evaluated using receiver operating characteristic (ROC) curves. A nomogram was developed for individualized risk prediction, and the model was internally validated using bootstrap resampling (1000 iterations), calibration curves, and decision curve analysis (DCA) to assess the clinical utility.</p>Results<p>Among the 93 Bethesda III thyroid nodules, 84 (90.32%) were malignant. Among the individual predictors, BRAF V600E exhibited the highest diagnostic performance (AUC = 0.736, 95% CI: 0.589–0.884). Compared with individual modalities, the combined multimodal model demonstrated a significantly improved diagnostic trend, with an AUC of 0.821 (95% CI: 0.653–0.989).</p>Conclusion<p>In a surgically enriched, high-risk cohort of patients with Bethesda III thyroid nodules, the multimodal model integrating TgAb, TPOAb, C-TIRADS, and BRAF V600E testing provides excellent auxiliary diagnostic value and can effectively guide preoperative risk stratification.</p> 2026-09-24T04:43:16Z Dataset Dataset 10.3389/fendo.2026.1919450 https://figshare.com/articles/dataset/Data_Sheet_2_A_malignancy_risk_prediction_model_for_Bethesda_category_III_thyroid_nodules_based_on_serological_indicators_C-TIRADS_and_BRAF_V600E_testing_pdf/33979756 CC BY 4.0